Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR-positive,HER2-negative in Advanced Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Not Yet RecruitingNCT06941142
What this trial is testing

Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 382
Testing effectiveness (Phase 2)Ended earlyNCT04227327
What this trial is testing

Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)

Who this might be right for
Advanced Breast Cancer
University of Milano Bicocca 31
Testing effectiveness (Phase 2)Study completedNCT03056755
What this trial is testing

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 383
Testing effectiveness (Phase 2)Study completedNCT04505826
What this trial is testing

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
Olema Pharmaceuticals, Inc. 153
Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Not applicableLooking for participantsNCT06856200
What this trial is testing

Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Who this might be right for
Advanced HR - Positive, HER2 - Negative Breast CancerResistant to (Neo)Adjuvant Endocrine Therapy
Fudan University 36
Early research (Phase 1)Active Not RecruitingNCT07557004
What this trial is testing

SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.

Who this might be right for
HR+ / HER2- Advanced Breast Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd. 30
Early research (Phase 1)Study completedNCT03854903
What this trial is testing

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Who this might be right for
Metastatic Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor Positive Breast Cancer
Georgetown University 19
Post-approval studies (Phase 4)UnknownNCT05809024
What this trial is testing

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Who this might be right for
Locally Advanced Breast CancerHormone Receptor Positive，HER2-negative Breast Cancer
Yongsheng Wang 100
Early research (Phase 1)Study completedNCT05159518
What this trial is testing

PRT2527 in Participants With Advanced Solid Tumors

Who this might be right for
SarcomaCastrate Resistant Prostate CancerHormone Receptor Positive HER2 Negative Breast Cancer+2 more
Prelude Therapeutics Incorporated 30
Testing effectiveness (Phase 2)Ended earlyNCT05176080
What this trial is testing

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Henan Cancer Hospital 46
Early research (Phase 1)Looking for participantsNCT06120283
What this trial is testing

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorAdvanced Breast CancerMetastatic Breast Cancer+5 more
BeOne Medicines 433
Testing effectiveness (Phase 2)Active Not RecruitingNCT06105632
What this trial is testing

Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Who this might be right for
Advanced or Metastatic Breast Cancer
Pfizer 333
Testing effectiveness (Phase 2)Study completedNCT02894398
What this trial is testing

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

Who this might be right for
Breast CancerHormone Receptor Positive TumorHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
iOMEDICO AG 388
Early research (Phase 1)Ended earlyNCT05194072
What this trial is testing

Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Who this might be right for
Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms+8 more
Seagen, a wholly owned subsidiary of Pfizer 250
Not applicableStudy completedNCT05022342
What this trial is testing

Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 595
Large-scale testing (Phase 3)Looking for participantsNCT06380751
What this trial is testing

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 788
Testing effectiveness (Phase 2)Study completedNCT03809988
What this trial is testing

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Who this might be right for
Breast CancerAdvanced Breast CancerHormone Receptor Positive Tumor+1 more
MedSIR 198
Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Next Page